A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab
The study revealed that durvalumab immunotherapy is associated with AEs including death, radiation pneumonitis, pneumonitis, metastases to the central nervous system, lung disorder and drug-induced liver injury. In clinical practice, it is crucial to be vigilant and prevent the occurrence of these AEs.
Authors
- Zhuoyang Li (ORCID: https://orcid.org/0009-0003-1631-3634)
- Tianhong Wang (ORCID: https://orcid.org/0000-0002-0331-3761)
- Yusi Hua (ORCID: https://orcid.org/0000-0003-1640-8388)
- Ting Zou (ORCID: https://orcid.org/0000-0002-8809-7390)
- Shuang Deng (ORCID: https://orcid.org/0009-0009-4025-0788)
- S. Wang
Institutions
- Sichuan University (CN)
- Southwest Medical University (CN)
- West China Hospital of Sichuan University (CN)
- Wuhan University of Science and Technology (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s40360-024-00821-y
- Citations
- 7
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 7.90